Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study

Pharmacological Reports

Volumn 60, Issue 6, 2008, Pages 957-965

  Haduch, Anna ^a   Wójcikowski, Jacek ^a   Daniel, Włladyslawa A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressants; Chronic treatment; CYP2B; Enzyme induction; Enzyme inhibition; In vitro study; One day treatment; Rat liver microsomes

Indexed keywords

16 BETA HYDROXYTESTOSTERONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450 2B; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; CYTOCHROME P450 2B1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER MICROSOME; MALE; NONHUMAN; NORADRENERGIC SYSTEM; RAT; SEROTONINERGIC SYSTEM; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME INDUCTION; ENZYMOLOGY; METABOLISM; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2B1; ENZYME INDUCTION; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR;

EID: 65249185691     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Anderson DT, Fritz KL, Muto JJ: Distribution of mirtazapine (Remeron) in thirteen postmortem cases. J Anal Toxicol 1993, 23, 544-548.
2. Anzenbacher P, Anzenbacherová E: Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci, 2001, 58, 737-747.
3. Arlotto MP, Trant JM, Estabrook RW: Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. In: Methods in Enzymology. Ed. Waterman MR, Johnson EF, Academic Press Inc., Harcourt Brace Jovanovich, Publishers, San Diego, California, USA, 1991, 206, 454-462.
4. Baumann P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol, 1996, 11, 5-11.
5. Caccia S, Cappi M, Fracasso C, Garattini S: Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl), 1990, 100, 509-514.
6. Coudore F, Fialip J, Eschalier A, Lavarenne J: Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. Eur J Drug Metab Pharmacokinet, 1994, 19, 5-13.
7. Daniel WA: Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27, 65-73.
8. Daniel WA: The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol, 2005, 1, 203-217.
9. Daniel WA, Adamus A, Melzacka M, Szymura J, Vetulani J: Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages. Naunyn Schmiedebergs Arch Pharmacol, 1983, 317, 209-213.
10. Daniel WA, Haduch A, Syrek M, Boksa J: Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol, 2006, 16, 580-587.
11. Daniel WA, Haduch A, Wójcikowski J: Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants. J Pharm Pharmacol, 2002, 54, 1545-1552.
12. Daniel W, Syrek M, Janczar L, Boksa J: The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats - a comparison with the pharmacokinetics of imipramine. Pol J Pharmacol, 1995, 47, 127-136.
13. Daniel WA, Wójcikowski J: Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol Toxicol, 1997, 80, 62-68.
14. Daniel WA, Wójcikowski J: The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol Appl Pharmacol, 1999, 158, 115-124.
15. Davis R, Whittington R, Bryson HM: Nefazodone. Drugs, 1997, 53, 608-636.
16. Desrochers M, Christou M, Jefcoate C, Belzil A, Anderson A: New protein in the rat CYP2B subfamily: presence in liver microsomes of the constitutive CYP2B3 protein and the phenobarbital-inducible protein product of alternatively spliced CYP2B2 mRNA. Biochem Pharmacol, 1996, 52, 1311-1319.
17. Ekins S, Wrighton SA: The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev, 1999, 31, 719-754.
18. Faucette SR, Sueyoshi R, Smith CM, Negishi M, LeCluyse EL, Wang H: Differential Regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther, 2006, 317, 1200-1209.
19. Fuller RW, Hemerick-Luecke SK, Littlefield ES, Audia JE: Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo. Prog Neuropsychopharmacol Biol Psychiatry, 1995, 135-149.
20. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H et al.: Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics, 1999, 9, 295-306.
21. Ghersi-Egea JF, Leninger-Muller B, Suleman G, Siest G, Minn A: Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J Neurochem, 1994, 62, 1089-1096.
22. Gokhale MS, Bunton TE, Zurlo J, Yager JD: Cytochrome P450 isoenzymes activities in cultured rat and mouse liver slices. Xenobiotica, 1997, 27, 341-355.
23. Goodnick PJ: Pharmacokinetic optimization of therapy with newer antidepressants. Clin Pharmacokinet, 1994, 27, 307-330.
24. Guengerich FP: Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact, 1997, 106, 161-182.
25. Haduch A, Bromek E, Kot M, Jemnitz K, Veres Z, Vereczkey L, Daniel WA.: Effect of mirtazapine on the CYP2D activity in the primary culture of rat hepatocytes. Pharmacol Rep, 2006, 58, 979-984.
26. Haduch A, Wójcikowski J, Daniel WA: The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment. Pharmacol Rep, 2007, 59, 606-612.
27. Haduch A, Wójcikowski J, Daniel WA: The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. Eur Neuropsychopharmacol, 2006, 16, 178-186.
28. Hanna IH, Reed JR, Guengerich FP, Hollenberg PF: Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys, 2000, 376, 206-216.
29. Heyn H, White RB, Stevens JC: Catalytic role of cytochrome P450 2B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos, 1996, 24, 948-954.
30. Holm KJ, Markham A: Mirtazapine. A review of its use in major depression. Drugs, 1999, 57, 607-631.
31. Honkakoski P, Negishi M: Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J, 2000, 347, 321-337.
32. Honkakoski P, Zelko I, Sueyoshi T, Negishi M: The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol, 1998, 18, 5652-5658.
33. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y: Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol, 1996, 51, 1041-1050.
34. Kapoor N, Pant AB, Dhawan A, Dwiewedi UN, Seth PK, Parmar D: Differences in the expression and inducibility of cytochrome P450 2B isoenzymes in cultured rat brain neuronal and glial cells. Mol Cell Biochem, 2007, 305, 199-207.
35. Kawamoto T, Kakizaki S, Yoshinari K, Negishi M: Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. Mol Endocrinol, 2000, 14, 1897-1905.
36. Kawamoto T, Sueyoshi T, Zelko I, Moore R, Washburn K, Negishi M: Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol, 1999, 19, 6318-6322.
37. Lee AM, Miksys S, Tyndale RF: Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. Br J Pharmacol, 2006, 148, 786-794.
38. Lewis DFV, Lake BG: Molecular modeling of mammalian CYP2B isoforms and their interactions with substrates, inhibitors and redox partners. Xenobiotica, 1997, 27, 443-478.
39. Miksys S, Hoffman E, Tyndale RF: Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol, 2000, 59, 1501-1511.
40. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF: Smoking, alcoholism and genetic polymorphism alter CYP2B6 levels in human brain. Neuropharmacology, 2003, 45, 122-132.
41. Miksys S, Tyndale RF: Brain drug-metabolizing cytochrome P450 enzymes are active on vivo, demonstrated by mechanism-based enzyme inhibition. Neuropsychopharmacology, 2008, doi: 10.1038/npp.2008.110.
42. Miksys S, Tyndale RF: Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm (Suppl), 2006, 70, 177-180.
43. Moore KA, Levine B, Smith ML, Saki S, Schames J, Smialek JE: Tissue distribution of mirtazapine (Remeron) in postmortem cases. J Anal Toxicol, 1999, 23, 541-543.
44. Mugford CA, Kedderis GL: Sex-dependent metabolism of xenobiotics. Drug Metab Rev, 1998, 30, 441-498.
45. Murayama N, Shimada M, Yamazoe Y, Kato R: Difference in the susceptibility of two phenobarbital-inducible forms, P450IIB1 and P450IIB2, to thyroid hormone-and growth hormone-induced suppression in rat liver: phenobarbital-inducible P450IIB2 suppression by thyroid hormone acting directly, but not through the pituitary system. Mol Pharmacol, 1991, 39, 811-817.
46. Murray M: Inhibition and induction of cytochrome P450 2B1 in rat liver by promazine and chlorpromazine. Biochem Pharmacol, 1992, 44, 1219-1222.
47. Rane A, Liu Z, Levol R, Bjelfman C, Thys C, Ericson H, Hansson T et al.: Differential effects of neuroleptic agents on hepatic cytochrome P-450 isoenzymes in the male rat. Biochim Biophys Acta, 1996, 1291, 60-66.
48. Rendic S, Di Carlo F: Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev, 1997, 29, 413-580.
49. Ryan DE, Levin W: Purification and characterization of hepatic microsomal cytochrome P-450 Pharmacol Ther, 1990, 45, 153-239.
50. Sanchez C, Hyttel J: Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol, 1999, 19, 467-489.
51. Schilter B, Omiecinski CJ: Regional distribution and expression modulation of cytochromeP-450 and epoxyde hydrolase mRNAs in the rat brain. Mol Pharmacol, 1993, 44, 990-996.
52. Schoedel KA, Sellers EM, Tyndale RF: Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem Pharmacol, 2001, 62, 1025-1036.
53. Schüle C: Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol, 2006, 19, 213-226.
54. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A: Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys, 1987, 255, 27-41.
55. Strom SC, Pisarov LA, Dorko K, Thompson MT, Schuetz JD, Schuetz EG: Use of human hepatocytes to study P450 gene induction. Methods Enzymol, 1996, 272, 388-401.
56. Timmer CJ, Sitsen JM, Delbressine LP: Clinical pharmacokinetics of mirtazapine, Clin Pharmacokinet, 2000, 38, 461-474.
57. Tirumalai PS, Bhamre S, Upadhya SC, Boyd BR, Ravindranath V: Expression of multiple forms of cytochrome P450 and associated mono-oxygenase activities in rat brain regions. Biochem Pharmacol, 1998, 56, 371-375.
58. Tremaine LM, Welch WM, Ronfeld RA: Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline on the rat and dog. Drug Metab Dispos, 1989, 17, 542-550.
59. Upadhya SC, Chinta SJ, Pai HV, Boyd MR, Ravindranath V: Toxicological consequences of differential regulation of cytochrome P450 isoforms in rat brain regions by phenobarbital. Arch Biochem Biophys, 2002, 399, 56-65.
60. van Harten J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet, 1993, 24, 203-220.
61. Wang H, Kawashima H, Strobel HW: cDNA cloning of a novel CYP3A from rat brain. Biochem Biophys Res Commun, 1996, 221, 157-162.
62. Wójcikowski J, Daniel WA: Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol J Pharmacol, 2000, 52, 449-457.
63. Wójcikowski J, Daniel WA: Thioridazine - fluoxetine interaction at the level of the distribution process in vitro. Pol J Pharmacol, 2002, 54, 647-654.
64. Wójcikowski J, Gołembiowska K, Daniel WA: Regulation of liver cytochrome P450 by activation of brain dopaminergic system: physiological and pharmacological implications. Biochem Pharmacol, 2008, 76, 258-267.
65. Wójcikowski J, Gołembiowska K, Daniel WA: The regulation of liver cytochrome P450 by the brain dopaminergic system. Curr Drug Metab, 2007, 8, 631-638.